Natco Pharma Approves Rights Issue of ₹1,279 Crore at ₹750/Share
Natco Pharma approved a rights issue of ₹1,279.36 crore by offering 17,058,082 equity shares at ₹750 each. The record date is October 1, 2026. The issue opens on October 12, 2026, and closes on October 22, 2026.
The rights issue is substantial in size (over ₹1,200 crore) and will dilute existing shareholding, impacting the capital structure and potentially share price.
The company is raising significant capital through a rights issue, which is generally viewed positively as it can fund growth or strengthen the balance sheet.
Natco Pharma Limited's Board of Directors, in a meeting held on September 25, 2026, approved a rights issue of equity shares to raise up to ₹1,279.36 crore. The issue will offer 17,058,082 equity shares of face value ₹2 each at a price of ₹750 per share, including a premium of ₹748 per share.
The rights issue is open to eligible equity shareholders as of the record date, October 1, 2026. The shares will be offered in the ratio of 2 rights equity shares for every 21 fully paid-up equity shares held. The rights issue period will commence on Monday, October 12, 2026, and close on Thursday, October 22, 2026. An on-market renunciation period will be available from October 12, 2026, to October 16, 2026.
The company also approved an amendment to its Code of Conduct for designated persons, which will be available on the company's investor relations website. The board meeting commenced at 10:30 a.m. and concluded at 11:00 a.m.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.